Recombinant Human SFTPC Protein，His

SFTPC, or Surfactant Protein C, is a key component of pulmonary surfactant, a mixture of lipids and proteins that reduces surface tension in the alveoli and plays a crucial role in lung function and host defense. Mutations in the SFTPC gene have been linked to various lung diseases, particularly surfactant dysfunction disorders such as interstitial lung diseases and surfactant metabolism disorders. Given its critical role in maintaining pulmonary health, there is growing interest in studying SFTPC as a therapeutic target and diagnostic marker. Research has focused on recombinant SFTPC proteins, which can be produced through genetic engineering techniques, enabling the exploration of their structure, function, and potential applications in treating lung diseases. By investigating the biophysical properties and interactions of recombinant SFTPC with lipids and other surfactant proteins, researchers aim to understand the mechanisms underlying surfactant metabolism and its implications for disease. Moreover, recombinant SFTPC has potential therapeutic applications in the development of novel surfactant replacement therapies for treating surfactant deficiency in neonates and adults. Additionally, understanding the kinetics of recombinant SFTPC can contribute to the design of targeted therapies for lung diseases associated with SFTPC mutations, opening new avenues for therapeutic interventions. Overall, the study of recombinant SFTPC proteins is a rapidly evolving field that combines molecular biology, biochemistry, and clinical research to address significant health challenges related to lung function and disease.